Nu Skin Enterprises, Inc. NUS

Consumer StaplesPersonal & Household Products & ServicesUnited States of America

Last close 4.65 USD on Nov 1, 2026, −50.2% year to date

Quant rating

Quant rating D Rank 102 of 124 in Consumer Staples

Growth C 67 of 124
Valuation B 21 of 124
Quality D 112 of 124
Revisions D 97 of 124
Momentum D 115 of 124

Wall Street consensus Average target 12.77 USD +174.6%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 226M
Enterprise value: 249M
52-week range: 4.45 – 11.66
3-year range: 4.45 – 20.32
Dividend yield: 5.16%
Beta (5 years): 0.92
Shares outstanding: 48.7M
Next earnings: Nov 5, 2026

About the company

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,485	1,732	1,969	2,226	2,696	–
Revenue growth	−14.3%	−12.0%	−11.5%	−17.4%	4.4%	−10.5%
EPS (basic, normalized)	1.27	0.84	1.85	2.90	4.14	–
EPS growth	51.2%	−54.6%	−36.2%	−30.0%	–	–
Gross margin	69.4%	68.2%	68.9%	71.7%	75.0%	70.6%
Net margin	10.8%	−8.5%	0.4%	4.7%	5.5%	2.6%
ROE	22.0%	−19.9%	1.0%	11.6%	16.3%	6.2%

Balance sheet, last quarter
Cash & short-term investments (mil)	191
Current ratio	1.98x
Long-term debt (mil)	194
Net debt (mil)	22.3
Total equity (mil)	543
Net debt / equity	0.04x
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,485	−14.3%	0.2x	–	–	–	1.27	+51.2%	3.7x
2026	1,317	−11.3%	0.2x	–	–	–	0.82	−35.4%	5.7x
2027	1,474	+12.0%	0.2x	–	–	–	1.16	+41.5%	4.0x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,317	0.0%	−7.6%	−7.7%	0.82	0.0%	−18.0%	−18.0%
2027	1,474	0.0%	−3.6%	−3.6%	1.16	0.0%	−12.1%	−11.5%
2028	–	–	–	–	–	–	–	–

Earnings surprises EPS beat in 1 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	417	439	430	446	364	386	364	370	321	320
Sales mean (mil)	427	432	441	436	–	–	374	383	330	345
Surprise	−2.2%	+1.7%	−2.5%	+2.2%	–	–	−2.7%	−3.2%	−2.8%	−7.3%
EPS reported	0.09	0.21	0.17	0.38	0.23	0.43	0.34	0.29	0.14	0.20
EPS mean	0.05	0.17	0.20	0.21	–	–	0.30	0.30	0.15	0.20
Surprise	+76.5%	+25.5%	−13.0%	+78.4%	–	–	+13.3%	−3.3%	−6.7%	0.0%

Peer comparison Personal & Household Products & Services

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
NUS Nu Skin Enterprises, Inc.	226M	–	10.8%	0.42x	5.7x	4.0x	–	–
OREP L'Oreal SA	260.5B	–	13.9%	6.87x	31.7x	28.8x	21.3x	19.7x
EL Estee Lauder Companies Inc	39.6B	1.53x	1.6%	10.38x	32.8x	27.3x	15.2x	13.4x
ELF e.l.f. Beauty, Inc.	6.6B	1.46x	1.6%	5.63x	30.7x	28.4x	17.6x	16.3x
IPAR Interparfums Inc	3.7B	0.52x	11.3%	4.28x	23.8x	22.1x	13.7x	12.7x
EPC Edgewell Personal Care Company	1.3B	2.93x	1.1%	0.90x	14.8x	14.3x	8.7x	8.3x
Mean		1.61x	6.7%	4.75x	23.2x	20.8x	15.3x	14.1x
Median		1.49x	6.2%	4.96x	27.3x	24.7x	15.2x	13.4x

Technical analysis

1M+0.2%
3M−10.3%
1Y−55.1%
3Y−72.1%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Nu Skin Enterprises, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,485	1,732	1,969	2,226	2,696	2,582
Cost of revenue	454	550	612	631	675	658
Gross profit	1,031	1,182	1,357	1,595	2,020	1,924
Selling, general & administrative expenses	930	1,118	1,267	1,412	1,707	1,643
Research & development	10.8	13.0	22.6	23.3	27.2	23.3
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	−151	202	19.8	48.5	51.9	0
Other operating expenses	0	0	0	0	0	0
Operating income	242	−152	48.3	111	234	258
Net interest income (expense)	−42.0	−26.4	−25.6	−13.5	−11.0	−13.1
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−3.7	2.9	3.9	−8.4	9.5	11.8
Net income before taxes	196	−175	26.6	89.0	232	256
Provision for taxes	36.0	−28.5	18.0	−15.8	85.2	64.9
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	160	−147	8.6	105	147	191
Extraordinary items	–	–	–	–	–	–
Net income	160	−147	8.6	105	147	191
EBIT, normalized	90.9	50.8	68.1	159	286	258
EBITDA, normalized	144	122	142	232	363	332
Basic EPS, normalized	1.27	0.84	1.85	2.90	4.14	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Nu Skin Enterprises, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	242	202	270	280	356	457
Receivables	39.5	50.8	72.9	47.4	41.3	63.4
Total inventory	179	190	280	346	400	314
Prepaid expenses	68.8	64.0	69.9	77.5	57.6	53.5
Other current assets	18.7	31.6	9.0	9.2	18.2	14.7
Total current assets	548	539	702	760	873	903
Property, plant & equipment	459	462	534	558	575	623
Goodwill	83.6	83.6	231	206	206	203
Intangibles	42.6	74.3	105	66.7	77.0	89.5
Long-term investments	18.7	39.6	36.4	39.5	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	254	271	198	191	175	138
Total assets	1,405	1,469	1,806	1,821	1,906	1,957
Liabilities
Accounts payable	26.2	34.9	43.5	54.0	50.0	66.2
Payable/accrued	–	–	–	–	–	–
Accrued expenses	194	144	185	196	308	353
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	20.0	30.0	25.0	25.0	108	30.0
Other current liabilities	23.5	87.4	75.1	83.8	64.3	94.0
Total current liabilities	264	297	329	359	530	543
Long-term debt	211	372	487	390	274	313
Minority interest	–	–	–	–	–	–
Other liabilities	126	149	168	175	190	207
Total liabilities	600	817	984	924	994	1,063
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.1	0.1	0.1	0.1	0.1	0.1
Additional paid-in capital	636	628	622	613	602	580
Retained earnings (accumulated deficit)	1,860	1,712	1,870	1,939	1,912	1,841
Treasury stock	−1,575	−1,564	−1,570	−1,569	−1,527	−1,462
Other equity	−116	−125	−100	−86.5	−73.9	−64.8
Total equity	805	651	822	897	913	894
Total liabilities & shareholders' equity	1,405	1,469	1,806	1,821	1,906	1,957

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Nu Skin Enterprises, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	160	−147	8.6	105	147	191
Depreciation, depletion & amortization	52.3	69.8	70.9	72.5	76.3	74.0
Deferred taxes	0	−55.5	−18.1	−51.6	5.8	−11.9
Non-cash items	−62.6	272	139	75.1	106	73.1
Changes in working capital	−69.6	−28.3	−81.7	−92.7	−194	52.6
Cash from operations	80.3	112	119	108	142	379
Investing activities
Capital expenditures	−34.3	−41.6	−58.5	−59.1	−68.6	−63.8
Other investing cash flows	205	3.6	−76.0	−8.0	−20.1	−15.6
Cash from investing	171	−38.0	−135	−67.1	−88.7	−79.4
Financing activities
Financing cash flow items	3.6	−6.3	0	−5.1	–	0
Cash dividends paid	−11.8	−11.9	−77.6	−77.0	−76.3	−78.4
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−194	−115	88.4	−17.4	−28.4	−167
Cash from financing	−202	−133	10.7	−99.5	−105	−245
Foreign exchange effects	3.2	−9.8	−3.5	−16.3	−11.2	12.5
Net change in cash	51.7	−69.2	−8.7	−74.9	−63.1	67.1
Free cash flow	46.0	70.2	60.1	49.0	73.0	315

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.